Antivascular endothelial growth factor agents for neovascular age-related macular degeneration

Journal of Ophthalmology

Volumn 2012, Issue , 2012, Pages

  Zampros, Ilias ^a   Praidou, Anna ^a   Brazitikos, Periklis ^a   Ekonomidis, Panagiotis ^a   Androudi, Sofia ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872711163     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2012/319728     Document Type: Review

References (71)

1. Bhisitkul R. B., Vascular endothelial growth factor biology: clinical implications for ocular treatments. British Journal of Ophthalmology 2006 90 12 1542 1547 2-s2.0-33845251640 10.1136/bjo.2006.098426 (Pubitemid 44862578)
2. Ng E. W., Adamis A. P., Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Canadian Journal of Ophthalmology 2005 40 3 352 368 2-s2.0-21744446220 (Pubitemid 40942262)
3. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Susan Harvey V., Dvorak H. F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983 219 4587 983 985 2-s2.0-0021111648
4. Ferrara N., Gerber H. P., LeCouter J., The biology of VEGF and its receptors. Nature Medicine 2003 9 6 669 676 2-s2.0-0037699954 10.1038/nm0603-669 (Pubitemid 36749215)
5. Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V., Ferrara N., Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989 246 4935 1306 1309 2-s2.0-0024818355 (Pubitemid 20066716)
6. Ferrara N., Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 2004 25 4 581 611 2-s2.0-4143136640 10.1210/er.2003-0027 (Pubitemid 39099316)
7. Praidou A., Androudi S., Brazitikos P., Karakiulakis G., Papakonstantinou E., Dimitrakos S., Angiogenic growth factors and their inhibitors in diabetic retinopathy. Current Diabetes Reviews 2010 6 5 304 312
8. Aiello L. P., Northrup J. M., Keyt B. A., Takagi H., Iwamoto M. A., Hypoxic regulation of vascular endothelial growth factor in retinal cells. Archives of Ophthalmology 1995 113 12 1538 1544 2-s2.0-0028826101
9. Karkkainen M. J., Mäkinen T., Alitalo K., Lymphatic endothelium: a new frontier of metastasis research. Nature Cell Biology 2002 4 1 E2 E5 2-s2.0-0036144374 10.1038/ncb0102-e2 (Pubitemid 34071967)
10. Olofsson B., Korpelainen E., Pepper M. S., Mandriota S. J., Aase K., Kumar V., Gunji Y., Jeltsch M. M., Shibuya M., Alitalo K., Eriksson U., Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 1998 95 20 11709 11714 2-s2.0-13144266696 10.1073/pnas.95.20.11709 (Pubitemid 28460479)
11. Bauer S. M., Bauer R. J., Liu Z. J., Chen H., Goldstein L., Velazquez O. C., Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels. Journal of Vascular Surgery 2005 41 4 699 707 2-s2.0-18344391843 10.1016/j.jvs.2005.01.015 (Pubitemid 40637671)
12. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risaut W., Nagy A., Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996 380 6573 435 439 2-s2.0-0343920277 10.1038/380435a0 (Pubitemid 26102719)
13. Ferrara N., Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Seminars in Oncology 2002 29 6 10 14 2-s2.0-0036985699
14. Yonekura H., Sakurai S., Liu X., Migita H., Wang H., Yamagishi S. I., Nomura M., Abedin M. J., Unoki H., Yamamoto Y., Yamamoto H., Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. Journal of Biological Chemistry 1999 274 49 35172 35178 2-s2.0-0033521040 10.1074/jbc.274.49.35172 (Pubitemid 129509573)
15. Stacker S. A., Caesar C., Baldwin M. E., Thornton G. E., Williams R. A., Prevo R., Jackson D. G., Nishikawa S. I., Kubo H., Achen M. G., VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nature Medicine 2001 7 2 186 191 2-s2.0-0035126049 10.1038/84635 (Pubitemid 32148485)
16. Takahashi H., Shibuya M., The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clinical Science 2005 109 3 227 241 2-s2.0-25144511910 10.1042/CS20040370 (Pubitemid 41337127)
17. Ishida S., Usui T., Yamashiro K., Kaji Y., Amano S., Ogura Y., Hida T., Oguchi Y., Ambati J., Miller J. W., Gragoudas E. S., Ng Y. S., D'Amore P. A., Shima D. T., Adamis A. P., VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. Journal of Experimental Medicine 2003 198 3 483 489 2-s2.0-0043125643 10.1084/jem.20022027 (Pubitemid 36976059)
18. McColm J. R., Geisen P., Hartnett M. E., VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Molecular Vision 2004 10 512 520 2-s2.0-4043153486 (Pubitemid 41358245)
19. Yi X., Ogata N., Komada M., Yamamoto C., Takahashi K., Omori K., Uyama M., Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefe's Archive for Clinical and Experimental Ophthalmology 1997 235 5 313 319 2-s2.0-0030999643
20. Keyt B. A., Berleau L. T., Nguyen H. V., Chen H., Heinsohn H., Vandlen R., Ferrara N., The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. Journal of Biological Chemistry 1996 271 13 7788 7795 2-s2.0-0029937679 10.1074/jbc.271.13.7788 (Pubitemid 26111064)
21. Ishida S., Usui T., Yamashiro K., Kaji Y., Ahmed E., Carrasquillo K. G., Amano S., Hida T., Oguchi Y., Adamis A. P., tony.adamis@eyetk.com VEGF164 is proinflammatory in the diabetic retina. Investigative Ophthalmology and Visual Science 2003 44 5 2155 2162 10.1167/iovs.02-0807 (Pubitemid 36520312)
22. Storkebaum E., Carmeliet P., VEGF: a critical player in neurodegeneration. Journal of Clinical Investigation 2004 113 1 14 18 2-s2.0-1542571389 10.1172/JCI200420682 (Pubitemid 38541624)
23. Jin K. L., Mao X. O., Greenberg D. A., Vascular endothelial growth factor rescues HN33 neural cells from death induced by serum withdrawal. Journal of Molecular Neuroscience 2000 14 3 197 203 2-s2.0-0033848792 (Pubitemid 30660810)
24. Sondell M., Lundborg G., Kanje M., Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. Journal of Neuroscience 1999 19 14 5731 5740 2-s2.0-0033565417 (Pubitemid 29327910)
25. Papapetropoulos A., García-Cardeña G., Madri J. A., Sessa W. C., Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. Journal of Clinical Investigation 1997 100 12 3131 3139 2-s2.0-2642597076 (Pubitemid 28022851)
26. Rakic J. M., Lambert V., Devy L., Luttun A., Carmeliet P., Claes C., Nguyen L., Foidart J. M., Noël A., Munaut C., Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Investigative Ophthalmology and Visual Science 2003 44 7 3186 3193 2-s2.0-0037900481 10.1167/iovs.02-1092 (Pubitemid 36759791)
27. Aiello L. P., Avery R. L., Arrigg P. G., Keyt B. A., Jampel H. D., Shah S. T., Pasquale L. R., Thieme H., Iwamoto M. A., Park J. E., Nguyen H. V., Aiello L. M., Ferrara N., King G. L., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 1994 331 22 1480 1487 2-s2.0-0027942607 10.1056/NEJM199412013312203 (Pubitemid 24356306)
28. Boyd S. R., Zachary I., Chakravarthy U., Allen G. J., Wisdom G. B., Cree I. A., Martin J. F., Hykin P. G., Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Archives of Ophthalmology 2002 120 12 1644 1650 2-s2.0-0036970074 (Pubitemid 36401798)
29. Noma H., Minamoto A., Funatsu H., Tsukamoto H., Nakano K., Yamashita H., Mishima H. K., Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 2006 244 3 309 315 2-s2.0-33646256581 10.1007/s00417-004-1087-4
30. Kvanta A., Algvere P. V., Berglin L., Seregard S., Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology and Visual Science 1996 37 9 1929 1934 2-s2.0-0029831672 (Pubitemid 26324159)
31. Praidou A., Papakonstantinou E., Androudi S., Georgiadis N., Karakiulakis G., Dimitrakos S., Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema. Acta Ophthalmologica 2011 89 248 254
32. Praidou A., Klangas I., Papakonstantinou E., Androudi S., Georgiadis N., Karakiulakis G., Dimitrakos S., Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Current Eye Research 2009 34 2 152 161 2-s2.0-60749113763 10.1080/02713680802585920
33. Adamis A. P., Miller J. W., Bernal M. T., D'Amico D. J., Folkman J., Yeo-T. K., Yeo K. T., Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. American Journal of Ophthalmology 1994 118 4 445 450 2-s2.0-0028123090 (Pubitemid 24307211)
34. Miller J. W., Adamis A. P., Shima D. T., D'Amore P. A., Moulton R. S., O'Reilly M. S., Folkman J., Dvorak H. F., Brown L. F., Berse B., Yeo T. K., Yeo K. T., Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. American Journal of Pathology 1994 145 3 574 584 2-s2.0-0028145249 (Pubitemid 24285965)
35. Blaauwgeers H. G., Holtkamp G. M., Rutten H., Witmer A. N., Koolwijk P., Partanen T. A., Alitalo K., Kroon M. E., Kijlstra A., Van Hinsbergh V. W. M., Schlingemann R. O., Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation. American Journal of Pathology 1999 155 2 421 428 2-s2.0-0032807809 (Pubitemid 29370392)
36. Adamis A. P., Shima D. T., Tolentino M. J., Gragoudas E. S., Ferrara N., Folkman J., D'Amore P. A., Miller J. W., Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Archives of Ophthalmology 1996 114 1 66 71 2-s2.0-0030067257 (Pubitemid 26026196)
37. Krzystolik M. G., Afshari M. A., Adamis A. P., Gaudreault J., Gragoudas E. S., Michaud N. A., Li W., Connolly E., O'Neill C. A., Miller J. W., Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Archives of Ophthalmology 2002 120 3 338 346 2-s2.0-0036129304 (Pubitemid 34250056)
38. Amano S., Rohan R., Kuroki M., Tolentino M., Adamis A. P., Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Investigative Ophthalmology and Visual Science 1998 39 1 18 22 2-s2.0-0031965601 (Pubitemid 28040457)
39. Ciulla T., Rosenfeld P., Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Current Opinion in Ophthalmology 2009 20 3 166 174 2-s2.0-65549136672 10.1097/ICU.0b013e328329d173
40. Steinbrook R., The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. New England Journal of Medicine 2006 355 14 1409 1412 2-s2.0-33749426139 10.1056/NEJMp068185 (Pubitemid 44511554)
41. Fine S. L., Berger J. W., Maguire M. G., Ho A. C., Age-related macular degeneration. New England Journal of Medicine 2000 342 7 483 492 2-s2.0-0034677435 10.1056/NEJM200002173420707 (Pubitemid 30100237)
42. Bird A. C., Bressler N. M., Bressler S. B., Chisholm I. H., Coscas G., Davis M. D., De Jong P. T. V. M., Klaver C. C. W., Klein B. E. K., Klein R., Mitchell P., Sarks J. P., Sarks S. H., Soubrane G., Taylor H. R., Vingerling J. R., An international classification and grading system for age-related maculopathy and age-related macular degeneration: the International ARM Epidemiological Study group. Survey of Ophthalmology 1995 39 5 367 374 2-s2.0-0028934221 10.1016/S0039-6257(05)80092-X
43. Waisbourd M., Loewenstein A., Goldstein M., Leibovitch I., Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs and Aging 2007 24 8 643 662 2-s2.0-34548107597 10.2165/00002512-200724080-00003
44. Rosenfeld P. J., prosenfeld@med.miami.edu Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006 355 14 1419 1431 10.1056/NEJMoa054481 (Pubitemid 44511557)
45. Jager R. D., Mieler W. F., Miller J. W., Age-related macular degeneration. New England Journal of Medicine 2008 358 24 2606 2617 2-s2.0-45149098715 10.1056/NEJMra0801537 (Pubitemid 351831361)
46. De Jong P. T., Age-Related Macular Degeneration. N Engl J Med. 2006 355 1474 1485 (Pubitemid 44511562)
47. Gragoudas E. S., evangelos-gragoudas@meei.harvard.edu Adamis A. P., Cunningham E. T. Jr., Feinsod M., Guyer D. R., Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine 2004 351 27 2805 2816 10.1056/NEJMoa042760 (Pubitemid 40051904)
48. Vingerling J. R., Dielemans I., Hofman A., Grobbee D. E., Hijmering M., Kramer C. F. L., De Jong P. T. V. M., The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology 1995 102 2 205 210 2-s2.0-0028839002
49. Regillo C. D., Brown D. M., Abraham P., Yue H., Ianchulev T., Schneider S., Shams N., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. American Journal of Ophthalmology 2008 145 2 239 248 2-s2.0-38349172455 10.1016/j.ajo.2007.10.004
50. Fung A. E., Lalwani G. A., Rosenfeld P. J., Dubovy S. R., Michels S., Feuer W. J., Puliafito C. A., Davis J. L., Flynn H. W., Esquiabro M., An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology 2007 143 4 566 583 2-s2.0-33947403618 10.1016/j.ajo.2007.01.028 (Pubitemid 46452533)
51. Bressler N. M., nmboffice@jhmi.edu Chang T. S., Fine J. T., Dolan C. M., Ward J., Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology 2009 127 1 13 21 10.1001/archophthalmol.2008.562
52. Brown D. M., Michels M., Kaiser P. K., Heier J. S., Sy J. P., Ianchulev T., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009 116 1 57 65 2-s2.0-57949094834 10.1016/j.ophtha.2008.10.018
53. Holz F. G., Frank.Holz@ukb.uni-bonn.de Amoaku W., Donate J., Guymer R. H., Kellner U., Schlingemann R. O., Weichselberger A., Staurenghi G., Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011 118 4 663 671 10.1016/j.ophtha.2010.12.019
54. Martin D. F., Maguire M. G., maguirem@mail.med.upenn.edu Ying G. S., Grunwald J. E., Fine S. L., Jaffe G. J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2011 364 20 1897 1908 10.1056/NEJMoa1102673
55. Singerman L. J., Masonson H., Patel M., Adamis A. P., Buggage R., Cunningham E., Goldbaum M., Katz B., Guyer D., Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF inhibition study in ocular neovascularisation (VISION) trial. British Journal of Ophthalmology 2008 92 12 1606 1611 2-s2.0-57149091202 10.1136/bjo.2007.132597
56. Feucht N., Matthias H., Lohmann C. P., Maier M., Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany. Clinical Ophthalmology 2008 2 253 259
57. Abouammoh M., Sharma S., sanjay-sharma60@hotmail.com Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. Current Opinion in Ophthalmology 2011 22 3 152 158 10.1097/ICU.0b013e32834595d0
58. Dixon J. A., Oliver S. C., Olson J. L., Mandava N., VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opinion on Investigational Drugs 2009 18 10 1573 1580 2-s2.0-70349330817 10.1517/13543780903201684
59. Nguyen Q. D., Shah S. M., Hafiz G., Quinlan E., Sung J., Chu K., Cedarbaum J. M., Campochiaro P. A., pcampo@jhmi.edu A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006 113 9 1522.e1 1522.e14 10.1016/j.ophtha.2006. 05.055 (Pubitemid 44292331)
60. Do D. V., Nguyen Q. D., Shah S. M., Browning D. J., Haller J. A., Chu K., Yang K., Cedarbaum J. M., Vitti R. L., Ingerman A., Campochiaro P. A., An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. British Journal of Ophthalmology 2009 93 2 144 149 2-s2.0-60849129118 10.1136/bjo.2008.138271
61. Barik S., Development of gene-specific double-stranded RNA drugs. Annals of Medicine 2004 36 7 540 551 2-s2.0-8544222783 10.1080/07853890410018817 (Pubitemid 39490963)
62. Fire A., Xu S., Montgomery M. K., Kostas S. A., Driver S. E., Mello C. C., Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 1998 391 6669 806 811 2-s2.0-0032545933 10.1038/35888 (Pubitemid 28099681)
63. Castanotto D., Rossi J. J., The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009 457 7228 426 433 2-s2.0-58749104364 10.1038/nature07758
64. Tolentino M. J., Brucker A. J., Fosnot J., Ying G. S., Wu I. H., Malik G., Wan S., Reich S. J., Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004 24 1 132 138 2-s2.0-1242297011 10.1097/00006982-200402000-00018 (Pubitemid 38240851)
65. Tolentino M. J., Brucker A. J., Fosnot J. Y., Ying G. S., Wu I. H., Malik G., Wan S., Reich S. J., Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in the nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004 24 4 660 2-s2.0-4043119134 10.1097/00006982-200408000-00039 (Pubitemid 39079909)
66. Garba A. O., Mousa S. A., Bevasiranib for the treatment of wet age-related macular degeneration. Journal of Ophthalmology and Eye Diseases 2010 2 75 83
67. Perkel J., RNAi therapeutics: a two-year update. Science 2009 326 454 456
68. Do D. V., ddo@jhmi.edu Schmidt-Erfurth U., Gonzalez V. H., Gordon C. M., Tolentino M., Berliner A. J., Vitti R., Rckert R., Sandbrink R., Stein D., Yang K., Beckmann K., Heier J. S., The da VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology 2011 118 9 1819 1826 10.1016/j.ophtha.2011.02.018
69. Cunningham E. T. Jr., Adamis A. P., Altaweel M., A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005 112 10 1747 1757 10.1016/j.ophtha.2005.06.007 (Pubitemid 41400011)
70. Kriechbaum K., Michels S., Prager F., Georgopoulos M., Funk M., Geitzenauer W., Schmidt-Erfurth U., Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. British Journal of Ophthalmology 2008 92 4 518 522 2-s2.0-41849095644 10.1136/bjo.2007.127282 (Pubitemid 351497981)
71. Schaal K. B., Höh A. E., Scheuerle A., Schütt F., Dithmar S., Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 2007 104 4 285 289 2-s2.0-34247469751 10.1007/s00347-007-1509-x